#IMVT

@nasdaq.activitypub.awakari.com.ap.brid.gy

3 months ago

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PL 4.5x
2. #GEMI 2.9x
3. #IMVT 2.4x
4. #EGO 2.2x
5. #BORR 2.2x

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Nasdaq

3 months ago

Why Is Roivant Sciences Stock Gaining Thursday? - Roivant Sciences (NASDAQ:ROIV) Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.

Roivant Signals Major Pipeline Momentum With Accelerated Timelines Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs. read more

#Biotech #IMVT #MRNA #News #ROIV #why #it's #moving #Health #Care #Top

Origin | Interest | Match

0 0 0 0

3 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PL, #GEMI, #IMVT, #EGO, #BORR

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Immunovant Announces Pricing of $550 Million Common Stock Financing Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an

3 months ago

#IMVT Immunovant Announces Pricing of $550 Million Common Stock Financing

www.stocktitan.net/news/IMVT/immunovant-ann...

0 0 0 0

Aurélie Biancarelli

@aureliebiancarelli.bsky.social

4 months ago

🎊 Rencontre étudiante !
J’étais ce soir à la soirée de fin d’année des étudiant•es de l’école d’Archi de #Marseille !
Un beau moment festif mais aussi l’occasion de discuter solidarité étudiante, lutte contre la précarité ou inclusion mais aussi partenariat !
#VieEtudiante
#IMVT
#Archi

1 0 0 0

4 months ago

#IMVT Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

www.stocktitan.net/news/IMVT/immunovant-pro...

0 0 0 0

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients Immunovant (NASDAQ: IMVT) has announced groundbreaking six-month remission data for its Graves' disease treatment. In a proof-of-concept study, ~80% (17/21) of patients maintained normal thyroid function six months after stopping batoclimab treatment. Notably, ~50% (8/17) of responders achieved anti-thyroid drug (ATD) free remission.The study evaluated batoclimab with a 24-week treatment period using a dose step-down protocol (680mg weekly for weeks 0-12, followed by 340mg weekly for weeks 12-24). The company is now advancing with two potentially registrational trials for its lead compound IMVT-1402, testing a 600mg dose for 52 weeks without step-down, with topline results expected in 2027.

7 months ago

#IMVT Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

www.stocktitan.net/news/IMVT/immunovant-unv...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Immunovant Posts 34% R&D Jump in Q1 | The Motley Fool

#IMVT #13d290ec-672f-44d0-acdc-9ac627778608 #data-news

Origin | Interest | Match

0 0 0 0

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 Immunovant (Nasdaq: IMVT) announced significant progress in its clinical development programs and financial results for Q2 2025. The company initiated two potentially registrational studies in June 2025: one for IMVT-1402 in Graves' disease (GD) and another for Sjögren's disease (SjD).The company maintains a strong financial position with $598.9 million in cash, providing runway through GD readout expected in 2027. R&D expenses increased to $101.2 million, up from $75.5 million year-over-year, while net loss widened to $120.6 million ($0.71 per share).Key upcoming milestones include batoclimab GD remission data in September 2025, and multiple trial results expected in 2026-2027 across various indications including D2T RA, CLE, GD, and MG.

7 months ago

#IMVT Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

www.stocktitan.net/news/IMVT/immunovant-pro...

0 0 0 0

Valérie Verdier

@valerieverdier.bsky.social

9 months ago

🗣️ Heureuse d’ouvrir à Marseille la 6e édition des #JIRD2025 à l’ #IMVT
Deux jours pour renforcer nos liens, partager nos stratégies et réfléchir collectivement à nos priorités scientifiques et géographiques. #IRD

2 1 0 0

Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs New data reveals strong efficacy in MG and CIDP trials with 74% improvement. $714M cash runway extends through 2027. See complete pipeline expansion details.

10 months ago

#IMVT Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

www.stocktitan.net/news/IMVT/immunovant-pro...

0 0 0 0

Clinical Trial Breakthrough: Immunovant's Batoclimab Shows Remarkable 74% Improvement in MG Patients New Phase 3 data reveals significant MG-ADL score improvements with Batoclimab, while CIDP study shows 84% response rate. Immunovant advances toward pivotal trials.

1 year ago

#IMVT Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

www.stocktitan.net/news/IMVT/immunovant-ann...

0 0 0 0

Aurélie Biancarelli

@aureliebiancarelli.bsky.social

1 year ago

Quand les étudiant•es de #IMVT se saisissent des enjeux de la @marseilleville.bsky.social pour réfléchir et imaginer le vivre et produire dans la ville de demain, les idées fusent !
Avec mes collègues Perinne Prigent et @mariebatoux.bsky.social nous étions présentes pour échanger avec elles et eux.

3 0 0 0

Immunovant's Massive $825M War Chest Fuels Race for Breakthrough Autoimmune Treatments Immunovant strengthens position with $825M cash balance and six IND clearances. Despite wider losses, company advances pivotal trials in Graves' disease and rheumatoid arthritis.

1 year ago

#IMVT Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

www.stocktitan.net/news/IMVT/immunovant-rep...

0 0 0 0

Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development Clinical-stage immunology firm Immunovant raises $450M through private stock sale at $20/share to advance IMVT-1402 development and strengthen pipeline initiatives.

1 year ago

#IMVT Immunovant Announces $450 Million Private Placement

www.stocktitan.net/news/IMVT/immunovant-ann...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #IMVT ) (IMVT) Investment Analysis and Advice

#StockMarket #News

0 0 0 0

Richard Loyen

@richardloyen.bsky.social

1 year ago

Le pire exemple, c'est l’Institut Méditerranéen de la Ville et des Territoires #IMVT récemment livré, qui rassemble en son sein les enseignements supérieurs en architecture, paysage et urbanisme, totalement vierge de panneaux solaires. Tout un symbole... 🤔

1 0 1 0

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #IMVT ) (IMVT) Investment Analysis

#StockMarket #News

1 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #IMVT ) Immunovant to Host Graves' Disease Program Update on September 9, 2024

#StockMarket #News

1 0 0 0

1 year ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ZETA, #EVRI, #UPS, #IMVT, #APLT

#OptionFlow #OptionsTrading #Trading

0 0 0 0